According to the analysis for each stage, the OS rates of stage III and stage IV patients with CD63 expression in cancer cells were significantly worse than those with CD63-negative expression (p < 0.0001 and p = 0.0063, respectively) (Fig 2A). Here, CD63 is linked to cancer.